Clinical trials: Vancomycin Treatment
Sepsis, Vancomycin Treatment
A New Protocol for Continuous Vancomycin Infusion Dosing.
This observational study prospectively collect data on chosen dosing, renal function, measured plasma concentrations and adherence to the recommended clinical protocl for ICU patients treated with continuous vancomycin infusion.
- Trial name
- CVIP (NCT05143645)
- Testing
- Plasma vancoymcin measurements
- Where
- Sweden
- Volunteers
- 101 people
- Sponsor
- Karolinska University Hospital
Bacterial Infections, Gram-Positive Bacterial Infections
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
- Conditions
- Bacterial Infections, Gram-Positive Bacterial Infections, Bacteremia
- Trial name
- NCT00037050
- Testing
- Linezolid, Vancomycin, Oxacillin
- Volunteers
- 739 people
- Sponsor
- Pfizer
Clostridium Enterocolitis, Pseudomembranous Colitis
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
The purpose of this study is to compare the outcome of treatment with nitazoxanide vs. vancomycin for diarrheal disease due to Clostridium difficile in patients who have failed previous treatment with metronidazole.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304889
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS2 (NCT00107978)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 1,035 people
- Sponsor
- Cumberland Pharmaceuticals
Infection, Hand Injury Wrist
Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration
The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (upper extremity) is more effective at preventing infection than the current standard dose…
- Conditions
- Infection, Hand Injury Wrist, Hand Injuries, Hand Injuries and Disorders
- Trial name
- NCT04673877
- Testing
- Systemic IV Vancomycin, Bier Block, Vancomycin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Methicillin-resistant Staphylococcus Aureus Septicemia
The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?
The purpose of this study is to evaluate which is the most appropriate parameter correlates with clinical effectiveness of vancomycin: trough drug level or AUC/MIC.
- Trial name
- NCT01995760
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- National Taiwan University Hospital
Wound Infection, Abscess
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic benefit of oritavancin administered as a…
- Conditions
- Wound Infection, Abscess, Systemic Inflammation, Cellulitis
- Trial name
- SOLO II (NCT01252732)
- Testing
- Single-Dose IV Oritavancin Diphosphate, IV Vancomycin
- Where
- United States
- Volunteers
- 1,019 people
- Sponsor
- Melinta Therapeutics, Inc.
C. Difficile, Diarrhea
Impact of Oral Antibiotic Treatment on C. Difficile
The overall aim is to characterize and to compare the extent and quantity of C. difficile stool shedding, perianal colonization and environmental contamination in patients who received oral fidaxomicin, oral metronidazole, or…
- Conditions
- C. Difficile, Diarrhea, Enterocolitis
- Trial name
- C-Diff (NCT02057198)
- Testing
- Fidaxomicin, Metronidazole, Vancomycin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Duke University
Gram-Positive Bacterial Infections, Staphylococcus Infections
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.
- Conditions
- Gram-Positive Bacterial Infections, Staphylococcus Infections, Vancomycin Resistance, Methicillin Resistance
- Trial name
- NCT00079976
- Testing
- Tigecycline
- Volunteers
- 174 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Total Knee Arthroplasty
IO Vancomycin Administration in TKA
This is a prospective, single-center, open-label study evaluating systemic vancomycin levels following preoperative intraosseous administration in patients undergoing primary unilateral total knee arthroplasty.
- Trial name
- IO Vanco (NCT07633418)
- Testing
- Intraosseous Vamcomycin Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.
- Trial name
- NCT07221708
- Testing
- Vancomycin (POC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Sepsis, Septic Shock
Specific miRNAs in Sepsis and Nephrotoxic Antibiotic Treatment
Critically ill patients are prone to develop acute kidney injury due to sepsis itself and by administration of potentially nephrotoxic antibiotic treatment (vancomycin or gentamicin).
- Conditions
- Sepsis, Septic Shock, Acute Kidney Injury
- Trial name
- NCT04991376
- Testing
- Blood-specific miRNA levels
- Where
- Czechia
- Volunteers
- 53 people
- Sponsor
- University Hospital Ostrava
Acute Bacterial Skin and Skin Structure Infections
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in…
- Trial name
- NCT03137173
- Testing
- ceftobiprole medocaril, vancomycin+aztreonam
- Where
- 34 sites in United States, Bulgaria and 2 more
- Volunteers
- 679 people
- Sponsor
- Basilea Pharmaceutica
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS1 (NCT00091819)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 862 people
- Sponsor
- Cumberland Pharmaceuticals
Vancomycin Therapy
Dose Enhancement of Vancomycin IN Everyday Patients
Current Australian guidelines for vancomycin commonly underdoses individuals particularly in the first 48 hours. The aim of the trial is to compare two dosing regimens; the current Australian guidelines versus a more…
- Trial name
- DEVINE (NCT01427842)
- Testing
- DEVINE vancomycin regimen
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- The Canberra Hospital
Acute Kidney Injury
A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients
Hospitalized patients with suspected or confirmed infection are commonly treated with vancomycin (VN) in combination with either piperacillin-tazobactam (PT) or cefepime (CP).
- Trial name
- MONACO (NCT06954129)
- Testing
- Vancomycin, Piperacillin-tazobactam, Cefepime
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- University of Pennsylvania
Community-acquired Pneumonia
Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin
This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for…
- Trial name
- STOP-Vanc (NCT06272994)
- Testing
- MRSA Nasal Swab PCR
- Where
- United States
- Volunteers
- 277 people
- Sponsor
- Vanderbilt University Medical Center
Clostridium Difficile Infection
Treatment of Initial Clostridium Difficile Infection
Investigators designed an open, two-arm study to compare oral vancomycin with a fecal microbiota transplant (FMT) from a fecal donor-unrelated donor mix (FURM) as treatments for the first Clostridium difficile infection (CDI)…
- Trial name
- NCT03107169
- Testing
- FMT, Vancomycin
- Volunteers
- 10 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Complicated Skin and Soft Tissue Infection
Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections.
- Trial name
- NCT02202135
- Testing
- Ceftaroline fosamil, Vancomycin, Aztreonam
- Where
- 22 sites in Argentina, Brazil and 11 more
- Volunteers
- 4 people
- Sponsor
- Pfizer
Clostridium Difficile Infection
Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?
This study evaluates whether patients with Clostridium difficile infection (CDI) who are treated with fidaxomicin have less contamination of their skin and surrounding environment with spores of C.
- Trial name
- NCT02461901
- Testing
- Environmental sampling, Skin swab sampling, Fecal sampling
- Where
- 3 sites in United Kingdom
- Volunteers
- 203 people
- Sponsor
- Professor Mark Wilcox